rTMS: To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
Psychotherapy: Using psychotherapy in opioid use disorder.
Study summary
This study aims to evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder, while also evaluating associated factors.
Eligibility
Sex
MALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion criteria:
* Male
* Age 18- 40
* Opioid use disorder
Exclusion criteria:
* Individuals with mental disorders (such as primary psychosis, schizophrenia, mental retardation, and brain damage induced mental disorder),
* History of epilepsy
* History of cardiovascular complications.
* History of contraindications to TMS (e.g. metal implants in the head).
Primary outcome measure(s)
Role of rTMS in managing opioid use disorders using multiple scales — 2 years To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain in patients with Opioid Use Disorder by using BRIEF PAIN INVENTORY (SHORT FORM) scale.
RTMS in managing opioid use disorder in Upper Egypt — 2 years Repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing craving in opioid use disorder patient using Brief Substance Craving Scale.
RTMS in managing opioid use disorder in Upper Egypt — 2 years Repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in improving cognition using Montreal Cognitive Assessment (MoCA) scale.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
